Gsk Plc (GSK.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-1995 | 06-1995 | 06-1994 | 06-1993 | 06-1992 | |
| Sales | 10,490,000 | 6,480,090 | 5,656,000 | 4,930,000 | 4,096,000 |
| Cost of Goods | N/A | 904,108 | N/A | N/A | N/A |
| Gross Profit | N/A | 5,575,982 | N/A | N/A | N/A |
| Operating Expenses | 6,920,000 | 4,122,175 | 3,843,000 | 3,410,000 | 2,803,000 |
| Operating Income | 3,570,000 | 1,453,807 | 1,813,000 | 1,520,000 | 1,293,000 |
| Interest Expense | 337,000 | N/A | 44,000 | 56,000 | 63,000 |
| Other Income | -846,000 | 62,103 | 66,000 | 211,000 | 197,000 |
| Pre-tax Income | 2,387,000 | 1,515,910 | 1,835,000 | 1,675,000 | 1,427,000 |
| Income Tax | 867,000 | 476,606 | 524,000 | 461,000 | 386,000 |
| Net Income Continuous | 1,520,000 | 1,039,303 | 1,311,000 | 1,214,000 | 1,041,000 |
| Minority Interests | -62,000 | -44,081 | -12,000 | -7,000 | -8,000 |
| Net Income | $1,458,000 | $1,039,303 | $1,299,000 | $1,207,000 | $1,033,000 |
| EPS Basic Total Ops | 0.56 | 0.41 | 0.53 | 0.50 | 0.43 |
| EPS Basic Continuous Ops | 0.56 | 0.41 | 0.53 | 0.50 | 0.43 |
| EPS Diluted Total Ops | 0.56 | 0.41 | 0.53 | 0.50 | 0.43 |
| EPS Diluted Continuous Ops | 0.56 | 0.41 | 0.53 | 0.50 | 0.43 |
| EBITDA(a) | $3,257,000 | $1,784,229 | $2,161,000 | $1,956,000 | $1,681,000 |